EPO pharma case law trends 2025: Clinical inventions

Clinical inventions are highly valuable in the pharma industry. Whilst the composition of matter patent for a drug will often define loss of exclusivity (LoE), patents that capture clinical-stage innovation can provide substantial value by bolstering protection beyond composition of matter expiry, and in some cases may even extend LoE (IPKat). The huge resource that pharma companies need to